118 related articles for article (PubMed ID: 38452727)
21. Discovery of chiral 1,4-diarylazetidin-2-one-based hydroxamic acid derivatives as novel tubulin polymerization inhibitors with histone deacetylase inhibitory activity.
Tang H; Liang Y; Yu M; Cai S; Ding K; Wang Y
Bioorg Med Chem; 2023 Sep; 92():117437. PubMed ID: 37563016
[TBL] [Abstract][Full Text] [Related]
22. A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo.
Li YR; Liu FF; Liu WB; Zhang YF; Tian XY; Fu XJ; Xu Y; Song J; Zhang SY
Biochem Pharmacol; 2022 Jul; 201():115070. PubMed ID: 35526597
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel non-toxic and anti-angiogenic α-fluorinated chalcones as potent colchicine binding site inhibitors.
Sun M; Yuan M; Kang Y; Qin J; Zhang Y; Duan Y; Wang L; Yao Y
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):339-354. PubMed ID: 34979843
[TBL] [Abstract][Full Text] [Related]
24. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.
Peng X; Chen J; Li L; Sun Z; Liu J; Ren Y; Huang J; Chen J
J Med Chem; 2021 Jun; 64(12):8447-8473. PubMed ID: 34097389
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of benzo[d]imidazo[2,1-b]thiazole-chalcone conjugates as microtubule targeting and apoptosis inducing agents.
Sultana F; Reddy Bonam S; Reddy VG; Nayak VL; Akunuri R; Rani Routhu S; Alarifi A; Halmuthur MSK; Kamal A
Bioorg Chem; 2018 Feb; 76():1-12. PubMed ID: 29102724
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of novel millepachine derivative containing aminophosphonate ester species as novel anti-tubulin agents.
Huang X; Wang M; Wang C; Hu W; You Q; Ma T; Jia Q; Yu C; Liao Z; Wang H
Bioorg Chem; 2020 Jan; 94():103486. PubMed ID: 31818482
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
Zhu H; Tan Y; He C; Liu Y; Duan Y; Zhu W; Zheng T; Li D; Xu J; Yang DH; Chen ZS; Xu S
J Med Chem; 2022 Aug; 65(16):11187-11213. PubMed ID: 35926141
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors.
Wang G; Peng F; Cao D; Yang Z; Han X; Liu J; Wu W; He L; Ma L; Chen J; Sang Y; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2013 Nov; 21(21):6844-54. PubMed ID: 23993668
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors.
An B; Zhang S; Yan J; Huang L; Li X
Org Biomol Chem; 2017 Jan; 15(4):852-862. PubMed ID: 28009925
[TBL] [Abstract][Full Text] [Related]
30. Design and discovery of new antiproliferative 1,2,4-triazin-3(2H)-ones as tubulin polymerization inhibitors targeting colchicine binding site.
Eissa IH; Dahab MA; Ibrahim MK; Alsaif NA; Alanazi AZ; Eissa SI; Mehany ABM; Beauchemin AM
Bioorg Chem; 2021 Jul; 112():104965. PubMed ID: 34020238
[TBL] [Abstract][Full Text] [Related]
31. A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics.
Al-Hamashi AA; Koranne R; Dlamini S; Alqahtani A; Karaj E; Rashid MS; Knoff JR; Dunworth M; Pflum MKH; Casero RA; Perera L; Taylor WR; Tillekeratne LMV
Bioorg Chem; 2021 Nov; 116():105297. PubMed ID: 34509798
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors.
Yang Z; Wu W; Wang J; Liu L; Li L; Yang J; Wang G; Cao D; Zhang R; Tang M; Wen J; Zhu J; Xiang W; Wang F; Ma L; Xiang M; You J; Chen L
J Med Chem; 2014 Oct; 57(19):7977-89. PubMed ID: 25208345
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Novel
Leng J; Zhao Y; Sheng P; Xia Y; Chen T; Zhao S; Xie S; Yan X; Wang X; Yin Y; Kong L
J Med Chem; 2022 Dec; 65(24):16774-16800. PubMed ID: 36471625
[TBL] [Abstract][Full Text] [Related]
34. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of new 2-chloro-4-aminopyrimidine and 2,6-dimethyl-4-aminopyrimidine derivatives as tubulin polymerization inhibitors.
Xu S; An B; Li Y; Luo X; Li X; Jia X
Bioorg Med Chem Lett; 2018 Jun; 28(10):1769-1775. PubMed ID: 29673981
[TBL] [Abstract][Full Text] [Related]
36. A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non-small cell lung cancers.
Liu Z; Huang L; Zhou T; Chang X; Yang Y; Shi Y; Hao M; Li Z; Wu Y; Guan Q; Zhang W; Zuo D
J Biol Chem; 2022 Jul; 298(7):102063. PubMed ID: 35618020
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
38. Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production.
Tang H; Liang Y; Cheng J; Ding K; Wang Y
Eur J Med Chem; 2021 Oct; 221():113531. PubMed ID: 34044345
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and antitumor evaluation of novel chiral diaryl substituted azetidin-2-one derivatives as tubulin polymerization inhibitors.
Liang Y; Zhang M; Zhou P; Liu M; Li J; Wang Y
Bioorg Chem; 2021 Oct; 115():105239. PubMed ID: 34399321
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of novel benzo[c]acridine-diones as potential anticancer agents and tubulin polymerization inhibitors.
Behbahani FS; Tabeshpour J; Mirzaei S; Golmakaniyoon S; Tayarani-Najaran Z; Ghasemi A; Ghodsi R
Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800307. PubMed ID: 31012156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
